Antifungal Drug Development: Challenges, Unmet Clinical Needs, and New Approaches
Open accessThe DOI matches its Crossref record; 77 of the 78 references it cites were found in a registry or an index.
Abstract
Invasive, life-threatening fungal infections are an important cause of morbidity and mortality, particularly for patients with compromised immune function. The number of therapeutic options for the treatment of invasive fungal infections is quite limited when compared with those available to treat bacterial infections. Indeed, only three classes of molecules are currently used in clinical practice and only one new class of antifungal drugs has been developed in the last 30 years. Here we summarize the unmet clinical needs of current antifungal therapy, discuss challenges inherent to antifungal drug discovery and development, and review recent developments aimed at addressing some of these challenges.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Organelles such as the vacuole make important contributions to tolerance and/or trailing growth.”
From Drug resistance and tolerance in fungi. (2020) · cites this paper as [94]
In the citing paper
“In Saccharomyces cerevisiae several genes involved in retrograde trafficking modulate tolerance and/or trailing growth, including VPS2127,51, VPS15 and VPS5194; Rim101 may influence tolerance via its ability to regulate the transcription of key components of the vacuolar trafficking pathway95.”
From Drug resistance and tolerance in fungi. (2020) · cites this paper as [94]
In the citing paper
“Despite extensive efforts, target-based cell-free screening of synthetic chemical libraries has failed to deliver any new classes of antifungals or antibacterials in clinical practice (Payne et al., 2007; Roemer and Krysan, 2014).”
From A Fungal-Selective Cytochrome bc1 Inhibitor Impairs Virulence and Prevents the Evolution of Drug Resistance (2016) · cites this paper as Roemer and Krysan, 2014
Citations
Cites
Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
Boucher, H. W., Talbot, G. H., Bradley, J. S., Edwards, J. E., Gilbert, D., Rice, L. B., Scheld, M., Spellberg, B., & Bartlett, J. (2009) · Clinical Infectious Diseases · doi:10.1086/595011 · Cited by 4,958
Functional profiling of the Saccharomyces cerevisiae genome
Giaever, G., Chu, A. M., Ni, L., Connelly, C., Riles, L., Véronneau, S., Dow, S., Lucau-Danila, A., Anderson, K., André, B., et al. (2002) · Nature · doi:10.1038/nature00935 · Cited by 4,316
Hidden Killers: Human Fungal Infections
Brown, G. D., Denning, D. W., Gow, N. A. R., Levitz, S. M., Netea, M. G., & White, T. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004404 · Cited by 4,284
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R. E., Oestmann, J.-W., Kern, W. V., Marr, K. A., Ribaud, P., Lortholary, O., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020191 · Cited by 3,304
Drugs for bad bugs: confronting the challenges of antibacterial discovery
Payne, D. J., Gwynn, M. N., Holmes, D. J., & Pompliano, D. L. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2201 · Cited by 2,512
The Genetic Landscape of a Cell
Costanzo, M., Baryshnikova, A., Bellay, J., Kim, Y., Spear, E. D., Sevier, C. S., Ding, H., Koh, J. L. Y., Toufighi, K., Mostafavi, S., et al. (2010) · Science · doi:10.1126/science.1180823 · Cited by 2,162
Park, B. J., Wannemuehler, K. A., Marston, B. J., Govender, N., Pappas, P. G., & Chiller, T. M. (2009) · AIDS · doi:10.1097/qad.0b013e328322ffac · Cited by 2,014
Platforms for antibiotic discovery
Lewis, K. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3975 · Cited by 1,445
Pierce, C. G., Uppuluri, P., Tristan, A. R., Wormley, F. L., Mowat, E., Ramage, G., & Lopez-Ribot, J. L. (2008) · Nature Protocols · doi:10.1038/nprot.2008.141 · Cited by 1,041
Amphotericin B formulations: a comparative review of efficacy and toxicity
Hamill, R. J. (2013) · Drugs · doi:10.1007/s40265-013-0069-4 · Cited by 807
Cited by
Items 101–200 of 620
Du, W., Zhai, P., Wang, T., Bromley, M. J., Zhang, Y., & Lu, L. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01839-20 · Cited by 46
Biofilm formation in clinically relevant filamentous fungi: a therapeutic challenge
Roudbary, M., Vahedi‐Shahandashti, R., dos Santos, A. L. S., Mohammadi, S. R., Aslani, P., Lass‐Flörl, C., & Rodrigues, C. F. (2021) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2021.1950121 · Cited by 51
Recent drug development and treatments for fungal infections
Roy, M., Karhana, S., Shamsuzzaman, M., & Khan, M. A. (2023) · Brazilian Journal of Microbiology · doi:10.1007/s42770-023-00999-z · Cited by 51
Woolford, C. A., Lagree, K., Xu, W., Aleynikov, T., Adhikari, H., Sanchez, H., Cullen, P. J., Lanni, F., Andes, D. R., & Mitchell, A. P. (2016) · PLOS Genetics · doi:10.1371/journal.pgen.1006487 · Cited by 47
Han, J., Liu, C., Li, L., Zhou, H., Liu, L., Li, B., Chen, Q., Song, F., Zhang, L., Li, E., et al. (2017) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.7b02010 · Cited by 46
Novel Antifungal Agents and Their Activity against Aspergillus Species
Vahedi‐Shahandashti, R., & Lass‐Flörl, C. (2020) · Journal of Fungi · doi:10.3390/jof6040213 · Cited by 51
Yan, Y., Zhou, B. O., Chen, Q., Vasquez, A., Kamra, M., Chatterjee, A., Lee, Y., Yuan, X., Ellis, L., Vizio, D. D., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28340-6 · Cited by 48
Paul, S., Bair, T. B., & Moye-Rowley, W. S. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03921-14 · Cited by 45
Kalem, M. C., Subbiah, H., Leipheimer, J., Glazier, V. E., & Panepinto, J. C. (2021) · mBio · doi:10.1128/mbio.03225-20 · Cited by 46
Sharma, K. K., Maurya, I. K., Khan, S. I., Jacob, M. R., Kumar, V., Tikoo, K., & Jain, R. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00481 · Cited by 45
Cho, S., Myong, J., Kim, W.-B., Park, C., Lee, S. J., Lee, S. H., & Lee, D. (2018) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph15112560 · Cited by 44
Nanomedicine as a promising strategy for the theranostics of infectious diseases
Liu, H., Zhong, W., Zhang, X., Lin, D., & Wu, J. (2021) · Journal of Materials Chemistry B · doi:10.1039/d1tb01316e · Cited by 44
Montoya, M. C., Beattie, S., Alden, K. M., & Krysan, D. J. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02331-19 · Cited by 42
Self-citationMudenda, S. (2024) · Pharmacology & Pharmacy · doi:10.4236/pp.2024.154007 · Cited by 51
Raja, V., Ahmad, S. I., Irshad, M., Wani, W. A., Siddiqi, W. A., & Shreaz, S. (2017) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2017.07.002 · Cited by 46
Chatterjee, S., Ghosh, R., & Mandal, N. C. (2019) · Microbiological Research · doi:10.1016/j.micres.2019.126386 · Cited by 41
Advances in fungal chemical genomics for the discovery of new antifungal agents
Xue, A., Robbins, N., & Cowen, L. E. (2020) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14484 · Cited by 43
Fungicidal Potency and Mechanisms of θ-Defensins against Multidrug-Resistant Candida Species
Basso, V., Garcia, A., Tran, D. Q., Schaal, J. B., Tran, P. A., Ngole, D., Aqeel, Y., Tongaonkar, P., Ouellette, A. J., & Selsted, M. E. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00111-18 · Cited by 44
Spore Germination as a Target for Antifungal Therapeutics
Ortiz, S. C., Huang, M., & Hull, C. M. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00994-19 · Cited by 41
Bari, V. K., Sharma, S., Alfatah, M., Mondal, A. K., & Ganesan, K. (2015) · Scientific Reports · doi:10.1038/srep09685 · Cited by 40
Montoya, M. C., DiDone, L., Heier, R. F., Meyers, M. J., & Krysan, D. J. (2017) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.7b00157 · Cited by 46
Self-citationNew antifungal strategies and drug development against WHO critical priority fungal pathogens
Li, Y., Liu, Y., Jiang, Y., Yang, Y., Ni, W., Zhang, W., & Tan, L. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1662442 · Cited by 53
Christian Martin, H., Ibáñez, R., Nothias-Scaglia, L.-F., P., C. A. B., Reinert, L. K., Rollins‐Smith, L. A., Dorrestein, P. C., & Gutiérrez, M. (2019) · Scientific Reports · doi:10.1038/s41598-019-39583-7 · Cited by 40
Haranahalli, K., Lazzarini, C., Sun, Y., Zambito, J., Pathiranage, S., McCarthy, J., Mallamo, J. P., Poeta, M. D., & Ojima, I. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01004 · Cited by 39
Sphingolipids: Regulators of azole drug resistance and fungal pathogenicity
Song, J., Xiao, L., & Li, R. (2020) · Molecular Microbiology · doi:10.1111/mmi.14586 · Cited by 39
Simm, C., Weerasinghe, H., Thomas, D. R., Harrison, P. F., Newton, H. J., Beilharz, T. H., & Traven, A. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.00100-22 · Cited by 38
“Despite this increasing threat, we have very few antimycotic drugs and our antifungal drug arsenal has not changed much in the last 30 years (2).”
BackgroundThe unmet clinical need of novel antifungal drugs
Krysan, D. J. (2017) · Virulence · doi:10.1080/21505594.2016.1276692 · Cited by 37
Self-citationHussain, M. A., Ahmed, D., Anwar, A., Perveen, S., Ahmed, S., Anis, I., Shah, M. R., & Khan, N. A. (2018) · International Microbiology · doi:10.1007/s10123-018-00043-3 · Cited by 38
Benzimidazole tethered pyrrolo[3,4-b]quinoline with broad-spectrum activity against fungal pathogens
Villa, P., Arumugam, N., Almansour, A. I., Kumar, R. S., Mahalingam, S. M., Maruoka, K., & Thangamani, S. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.01.006 · Cited by 37
Stavrou, A. A., Hansen, A. P., Lackner, M., Lass‐Flörl, C., & Boekhout, T. (2020) · Medical Mycology · doi:10.1093/mmy/myaa005 · Cited by 38
Kenno, S., Speth, C., Rambach, G., Binder, U., Chatterjee, S., Caramalho, R., Haas, H., Lass-Flörl, C., Shaughnessy, J., Ram, S., et al. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.03319 · Cited by 36
Khosravi, A., Sharifzadeh, A., Nikaein, D., Almaie, Z., & Gandomi, H. (2018) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2018.01.005 · Cited by 45
Promising New Antifungal Treatment Targeting Chorismate Synthase from Paracoccidioides brasiliensis
Rodrigues-Vendramini, F. A. V., Marschalk, C., Toplak, M., Macheroux, P., Mendonca, P., Svidzinski, T. I. E., Seixas, F. A. V., & Kioshima, É. S. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01097-18 · Cited by 40
Fu, Y., Estoppey, D., Roggo, S. P., Pistorius, D., Fuchs, F., Studer, C., Ibrahim, A. S., Aust, T., Grandjean, F., MIHALIC, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17221-5 · Cited by 40
RNA-Targeting Splicing Modifiers: Drug Development and Screening Assays
Tang, Z., Zhao, J., Pearson, Z., Bošković, Ž., & Wang, J. (2021) · Molecules · doi:10.3390/molecules26082263 · Cited by 39
Photodynamic Therapy Is Effective Against Candida auris Biofilms
Bapat, P. S., & Nobile, C. J. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.713092 · Cited by 35
An insight into new strategies to combat antifungal drug resistance
Zheng, Y., Ma, Y., Ding, Y., Chen, X., & Gao, G. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s185833 · Cited by 37
Nosratabadi, M., Rahimnia, S. M., Barough, R. E., Abastabar, M., Haghani, I., Akhtari, J., Hajheydari, Z., & Ebrahimnejad, P. (2024) · Scientific Reports · doi:10.1038/s41598-024-79225-1 · Cited by 36
Helsel, M. E., White, E. J., Razvi, S. Z. A., Aliès, B., & Franz, K. J. (2016) · Metallomics · doi:10.1039/c6mt00172f · Cited by 38
Histone deacetylase–mediated regulation of endolysosomal pH
Prasad, H., & Rao, R. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.002025 · Cited by 36
Structure-guided approaches to targeting stress responses in human fungal pathogens
LeBlanc, E. V., Polvi, E. J., Veri, A. O., Privé, G. G., & Cowen, L. E. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.rev120.013731 · Cited by 35
A Cationic Polymer That Shows High Antifungal Activity against Diverse Human Pathogens
Rank, L. A., Walsh, N. M., Liu, R., Lim, F. Y., Bok, J. W., Huang, M., Keller, N. P., Gellman, S. H., & Hull, C. M. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00204-17 · Cited by 34
Chhetri, A., Loksztejn, A., Nguyen, H. D., Pianalto, K. M., Kim, M. J., Hong, J., Alspaugh, J. A., & Yokoyama, K. (2020) · Biochemistry · doi:10.1021/acs.biochem.9b00896 · Cited by 35
Sharma, K. K., Ravi, R., Maurya, I. K., Kapadia, A., Khan, S. I., Kumar, V., Tikoo, K., & Jain, R. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113635 · Cited by 34
Molecular association of Candida albicans and vulvovaginal candidiasis: focusing on a solution
David, H., & Solomon, A. P. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1245808 · Cited by 38
Chemogenomic Profiling of the Fungal Pathogen Candida albicans
Chen, Y., Mallick, J., Maqnas, A., Sun, Y., Choudhury, B. I., Côte, P., Yan, L., Ni, T.-J.-H., Li, Y., Zhang, D., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02365-17 · Cited by 29
Strategies in the Discovery of Novel Antifungal Scaffolds
Liu, N., Wang, C., Su, H., Zhang, W., & Sheng, C. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0020 · Cited by 34
Troponoids Can Inhibit Growth of the Human Fungal Pathogen Cryptococcus neoformans
Donlin, M. J., Zunica, A., Lipnicky, A., Garimallaprabhakaran, A. K., Berkowitz, A. J., Grigoryan, A., Meyers, M. J., Tavis, J. E., & Murelli, R. P. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02574-16 · Cited by 34
Aryl-alkyl-lysines: Membrane-Active Fungicides That Act against Biofilms of Candida albicans
Ghosh, C., Yadav, V., Younis, W., Mohammad, H. T., Hegazy, Y. A., Seleem, M. N., Sanyal, K., & Haldar, J. (2017) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.6b00192 · Cited by 35
Demuyser, L., Swinnen, E., Fiori, A., Herrera-Malaver, B., Verstrepen, K., & Van Dijck, P. (2017) · mBio · doi:10.1128/mbio.00201-17 · Cited by 33
“The number of drugs available against fungal infections is limited, and those that are commonly used often suffer from being fungistatic rather than fungicidal (2, 3).”
Eldesouky, H. E., Salama, E. A., Hazbun, T. R., Mayhoub, A. S., & Seleem, M. N. (2020) · Scientific Reports · doi:10.1038/s41598-020-62976-y · Cited by 33
Novel and potent antimicrobial effects of caspofungin on drug-resistant Candida and bacteria
Sumiyoshi, M., Miyazaki, T., Makau, J. N., Mizuta, S., Tanaka, Y., Ishikawa, T., Makimura, K., Hirayama, T., Takazono, T., Saijo, T., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-74749-8 · Cited by 38
Rieske head domain dynamics and indazole-derivative inhibition of Candida albicans complex III
Di Trani, J. M., Liu, Z., Whitesell, L., Brzezinski, P., Cowen, L. E., & Rubinstein, J. L. (2022) · Structure · doi:10.1016/j.str.2021.08.006 · Cited by 32
RNA–Small-Molecule Interaction: Challenging the “Undruggable” Tag
Kaur, J., Sharma, A., Mundlia, P., Sood, V., Pandey, A., Singh, G., & Barnwal, R. P. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01354 · Cited by 35
Antimicrobial Photodynamic Therapy for Superficial, Skin, and Mucosal Fungal Infections: An Update
da Silva, L. B. B., Castilho, I. G., Silva, F. A. D. S., Ghannoum, M. A., Garcia, M. T., & do Carmo, P. H. F. (2025) · Microorganisms · doi:10.3390/microorganisms13061406 · Cited by 34
Nikalje, A. P., Tiwari, S. V., Sarkate, A. P., & Karnik, K. S. (2017) · Medicinal Chemistry Research · doi:10.1007/s00044-017-2085-5 · Cited by 33
Mahmoudi, S., Rezaie, S., Ghazvini, R. D., Hashemi, S. J., Badali, H., Foroumadi, A., Diba, K., Chowdhary, A., Meis, J. F. G. M., & Khodavaisy, S. (2019) · Mycopathologia · doi:10.1007/s11046-019-00370-7 · Cited by 33
Efficacy of essential oil of cinnamon for the treatment of oral candidiasis: A randomized trial
de Araújo, M. R. C., Maciel, P. P., Castellano, L. R. C., Bonan, P. R. F., Alves, D. D. N., de Medeiros, A. C. D., & de Castro, R. D. (2021) · Special Care in Dentistry · doi:10.1111/scd.12570 · Cited by 32
Ellagic Acid–Cyclodextrin Complexes for the Treatment of Oral Candidiasis
Sampaio, A. D. G., Gontijo, A. V. L., Lima, G. D. M. G., de Oliveira, M. A. C., Lepesqueur, L. S. S., & Koga‐Ito, C. Y. (2021) · Molecules · doi:10.3390/molecules26020505 · Cited by 33
Bapat, P. S., Singh, G., & Nobile, C. J. (2021) · Microorganisms · doi:10.3390/microorganisms9030500 · Cited by 34
dos Reis, T. F., Horta, M. A. C., Colabardini, A. C., Fernandes, C. M., Silva, L. P., Bastos, R. W., Fonseca, M. V. D. L., Wang, F., Martins, C., Rodrigues, M. L., et al. (2021) · mBio · doi:10.1128/mbio.01458-21 · Cited by 34
New insights into TB physiology suggest untapped therapeutic opportunities
Baer, C. E., Rubin, E. J., & Sassetti, C. M. (2015) · Immunological Reviews · doi:10.1111/imr.12267 · Cited by 33
Targeting a critical step in fungal hexosamine biosynthesis
Lockhart, D. E. A., Stanley, M., Raimi, O. G., Robinson, D. A., Boldovjáková, D., Squair, D. R., Ferenbach, A. T., Fang, W., & van Aalten, D. M. F. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.012985 · Cited by 31
Haroun, M., Tratrat, C., Kochkar, H., & Nair, A. B. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026621999201214232018 · Cited by 31
Xu, H., Yan, Z.-Z., Guo, M., An, R., Wang, X., Zhang, R., Mou, Y., Hou, Z., & Guo, C. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113337 · Cited by 30
Nagy, F., Tóth, Z., Nyikos, F., Forgács, L., Jakab, Á., Borman, A. M., Majoros, L., & Kovács, R. (2021) · Medical Mycology · doi:10.1093/mmy/myab032 · Cited by 31
Fattouh, N., Hdayed, D., Geukgeuzian, G., Tokajian, S. T., & Khalaf, R. A. (2021) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2021.103575 · Cited by 32
Mohammad, H., Elghazawy, N. H., Eldesouky, H. E., Hegazy, Y. A., Younis, W., Avrimova, L., Hazbun, T., Arafa, R. K., & Seleem, M. N. (2018) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.7b00215 · Cited by 29
Luna-Tapia, A., Willems, H. M. E., Parker, J. E., Tournu, H., Barker, K. S., Nishimoto, A. T., Rogers, P. D., Kelly, S. L., Peters, B. M., & Palmer, G. E. (2018) · mBio · doi:10.1128/mbio.00225-18 · Cited by 29
Kato, I., Ukai, Y., Kondo, N., Nozu, K., Kimura, C., Hashimoto, K., Mizusawa, E., Maki, H., Naito, A., & Kawai, M. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00883 · Cited by 30
Envisaging Antifungal Potential of Histatin 5: A Physiological Salivary Peptide
Sharma, P., Chaudhary, M., Khanna, G., Rishi, P., & Kaur, I. P. (2021) · Journal of Fungi · doi:10.3390/jof7121070 · Cited by 31
Discovery of Natural Products With Antifungal Potential Through Combinatorial Synergy
Augostine, C. R., & Avery, S. V. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.866840 · Cited by 35
Application of anti-fungal vaccines as a tool against emerging anti-fungal resistance
Kumar, R., & Srivastava, V. (2023) · Frontiers in Fungal Biology · doi:10.3389/ffunb.2023.1241539 · Cited by 30
Fang, T., Xiong, J., Wang, L., Feng, Z., Hang, S., Yu, J., Li, W., Feng, Y., Lu, H., & Jiang, Y. (2023) · Antibiotics · doi:10.3390/antibiotics12121675 · Cited by 27
Pries, V., Nöcker, C., Khan, D., Johnen, P., Hong, Z., Tripathi, A., Keller, A., Fitz, M., Perruccio, F., Filipuzzi, I., et al. (2018) · Cell chemical biology · doi:10.1016/j.chembiol.2017.12.007 · Cited by 29
Rising to the challenge of multiple Cryptococcus species and the diseases they cause
Idnurm, A., & Lin, X. (2015) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2015.05.002 · Cited by 34
Billmyre, R. B., Craig, C. J., Lyon, J. W., Reichardt, C., Kuhn, A. M., Eickbush, M. T., & Zanders, S. E. (2025) · PLoS Biology · doi:10.1371/journal.pbio.3003184 · Cited by 32
Broad-spectrum antifungal activities and mechanism of drimane sesquiterpenoids
Edouarzin, E., Horn, C., Paudyal, A., Zhang, C., Lu, J., Tong, Z., Giaever, G. N., Nislow, C., Veerapandian, R., Hua, D. H., et al. (2020) · Microbial Cell · doi:10.15698/mic2020.06.719 · Cited by 30
Singh, U., Singh, P., Singh, A. K., Laxmi, L., Kumar, D., Tilak, R., Shrivastava, S. K., & Asthana, R. K. (2021) · Algal Research · doi:10.1016/j.algal.2021.102215 · Cited by 31
Molecular Docking and Multivariate Analysis of Xanthones as Antimicrobial and Antiviral Agents
Bernal, F. A., & Coy-Barrera, E. D. (2015) · Molecules · doi:10.3390/molecules200713165 · Cited by 29
Sphingolipids as Regulators of the Phagocytic Response to Fungal Infections
Bryan, A. M., Poeta, M. D., & Luberto, C. (2015) · Mediators of Inflammation · doi:10.1155/2015/640540 · Cited by 29
The progress and future of the treatment of Candida albicans infections based on nanotechnology
Gao, Y., Cao, Q., Xiao, Y., Wu, Y., Ding, L., Huang, H., Li, Y., Yang, J., & Meng, L. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02841-6 · Cited by 33
Recent developments in Aspergillus fumigatus research: diversity, drugs, and disease
Kordana, N. E., Johnson, A., Quinn, K., Obar, J. J., & Cramer, R. A. (2025) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00011-23 · Cited by 29
Silva, L. N., de Mello, T. P., Ramos, L. S., Branquinha, M. H., & dos Santos, A. L. S. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666191025152412 · Cited by 29
Li, S., Wang, Y., Zhou, J., Wang, J., Zhang, M., & Chen, H. (2023) · Molecules · doi:10.3390/molecules28073098 · Cited by 29
Regulated Cell Death as a Therapeutic Target for Novel Antifungal Peptides and Biologics
Yeaman, M. R., Büttner, S., & Thevissen, K. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/5473817 · Cited by 28
Tits, J., Cools, F., Cremer, K. D., Brucker, K. D., Berman, J. G., Verbruggen, K., Gevaert, B., Cos, P., Cammue, B. P. A., & Thevissen, K. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01296-20 · Cited by 30
Zinc and Iron Homeostasis: Target-Based Drug Screening as New Route for Antifungal Drug Development
Simm, C., & May, R. C. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00181 · Cited by 26
Killer yeasts: expanding frontiers in the age of synthetic biology
Billerbeck, S., Walker, R. S. K., & Pretorius, I. S. (2024) · Trends in biotechnology · doi:10.1016/j.tibtech.2024.03.003 · Cited by 31
Stepping out of the dark: how metabolomics shed light on fungal biology
Adejor, J., Tumukunde, E., Li, G., Alhaji, T. S., Wu, L., Jiang, Z., & Wang, S. (2025) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuaf028 · Cited by 26
Antifungal resistance: Emerging mechanisms and implications (Review)
Kadariswantiningsih, I. N., Empitu, M. A., Santosa, T., & Alimu, Y. (2025) · Molecular Medicine Reports · doi:10.3892/mmr.2025.13612 · Cited by 30
Immunoproteomics of Aspergillus for the development of biomarkers and immunotherapies
Kniemeyer, O., Ebel, F., Krüger, T., Bächer, P., Scheffold, A., Luo, T., Straßburger, M., & Brakhage, A. A. (2016) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201600053 · Cited by 26
Pippi, B., Joaquim, A. R., Lopes, W., Machado, G. D. R. M., Bergamo, V. Z., Giuliani, L. M., Abegg, M. A., Cruz, L., Vainstein, M. H., Fuentefría, A. M., et al. (2019) · Journal of Applied Microbiology · doi:10.1111/jam.14545 · Cited by 30
Antifungal Drugs: The Current Armamentarium and Development of New Agents
Robbins, N., Wright, G. D., & Cowen, L. E. (2017) · ASM Press eBooks · doi:10.1128/9781555819583.ch44 · Cited by 27
Jothi, R., Prasath, N. H., Gowrishankar, S., & Pandian, S. K. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.781790 · Cited by 25
Advances in Antifungal Development: Discovery of New Drugs and Drug Repurposing
Jong Heon, K. I. M., Cheng, L. W., & Land, K. M. (2022) · Pharmaceuticals · doi:10.3390/ph15070787 · Cited by 30
Fungal cell barriers and organelles are disrupted by polyhexamethylene biguanide (PHMB)
Ntow‐Boahene, W., Papandronicou, I., Miculob, J., & Good, L. (2023) · Scientific Reports · doi:10.1038/s41598-023-29756-w · Cited by 28
Santra, H. K., Dutta, R., & Banerjee, D. (2024) · Scientific Reports · doi:10.1038/s41598-024-60948-0 · Cited by 27
Backes, G. L., Jursic, B. S., & Neumann, D. M. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.04.040 · Cited by 25
Basso, V., Tran, D. Q., Schaal, J. B., Tran, P. A., Eriguchi, Y., Ngole, D., Cabebe, A. E., Park, A. Y., Beringer, P. M., Ouellette, A. J., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-53402-z · Cited by 25
Metadata
- Authors
- Roemer, T., & Krysan, D. J.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- University of Rochester Medicine (US)
- ORCID
- Krysan, D. J.
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2014-05-01
- Volume
- 4
- Issue
- 5
- Pages
- a019703-a019703
- ISSN
- 2157-1422 (ISSN-L)
- PMC
- PMC3996373
- OpenAlex
- W2134122507
- Cited by
- 593
- References
- 78
- Citations by year
- 2026: 39 · 2025: 56 · 2024: 69 · 2023: 51 · 2022: 58 · 2021: 68 · 2020: 71 · 2019: 42 · 2018: 50 · 2017: 38 · 2016: 30 · 2015: 18 · 2014: 3
- Type
- posted content
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cold Spring Harbor Perspectives in Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Rochester
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases (R01AI097142, R01AI091422)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Keywords
- antifungal drug development, invasive fungal infections, antifungal drug discovery, unmet clinical needs, immunocompromised patients
- MeSH terms
- Antifungal Agents, Forecasting, Humans, Mycoses, Technology, Pharmaceutical, Treatment Outcome, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.